|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PGC |
 Gene summary |
| Basic gene Info. | Gene symbol | PGC |
| Gene name | progastricsin (pepsinogen C) | |
| Synonyms | PEPC|PGII | |
| Cytomap | UCSC genome browser: 6p21.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001166424.1, NM_002630.3, | |
| Description | gastricsinpepsin Cpepsinogen Cpepsinogen group IIpreprogastricsin | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 169740 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000096088 | ||
| HPRD : 01357 | ||
| Vega : OTTHUMG00000014683 | ||
| Protein | UniProt: P20142 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PGC | |
| BioGPS: 5225 | ||
| Pathway | NCI Pathway Interaction Database: PGC | |
| KEGG: PGC | ||
| REACTOME: PGC | ||
| Pathway Commons: PGC | ||
| Context | iHOP: PGC | |
| ligand binding site mutation search in PubMed: PGC | ||
| UCL Cancer Institute: PGC | ||
| Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
| References showing study about ligand binding site mutation for PGC. | 1. Li, Y., Kovach, A., Suino-Powell, K., Martynowski, D., & Xu, H. E. (2008). Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor γ to PGC-1α. Journal of Biological Chemistry,283(27), 19132-19139. 18469005 | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for PGC |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | N170 | T169A | COAD | 1 | F90 | T92I | COAD | 1 | F74 | F74C | KIRC | 1 | G223 | G223R | SKCM | 1 | M66 | E64K | SKCM | 1 | A204 | A204T | STAD | 1 | A204 | A204T | UCEC | 1 | Y173 | V172I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PGC |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | N170 | T169A | -1.4406285 | Y173 | V172I | -1.3277379 | A204 | A204T | -1.2249703 | M66 | E64K | -1.138195 | G223 | G223R | -0.62992496 | F74 | F74C | -0.30700237 | F90 | T92I | -0.24111835 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PGC from PDB |
| Top |
| Differential gene expression and gene-gene network for PGC |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PGC |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PGC |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PGC go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of PGC |
| Multiple alignments for P20142 in multiple species |
| LBS | AA sequence | # species | Species | A174 | TNFVYAQFDGI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A204 | MLGEGALSQPL | 2 | Mus musculus, Rattus norvegicus | A204 | MVQEGALTSPV | 1 | Homo sapiens | A224 | GSNGGQIVFGG | 2 | Mus musculus, Rattus norvegicus | A224 | GSSGGAVVFGG | 1 | Homo sapiens | A71 | MAYMDAAYFGE | 1 | Homo sapiens | A71 | MAYMDASYYGE | 1 | Mus musculus | A71 | MAYMDASYFGE | 1 | Rattus norvegicus | A72 | AYMDAAYFGEI | 1 | Homo sapiens | A72 | AYMDASYYGEI | 1 | Mus musculus | A72 | AYMDASYFGEI | 1 | Rattus norvegicus | D231 | VFGGVDSSLYT | 1 | Homo sapiens | D231 | VFGGVDENLYT | 1 | Mus musculus | D231 | VFGGVDKNLYT | 1 | Rattus norvegicus | D70 | PMAYMDAAYFG | 1 | Homo sapiens | D70 | PMAYMDASYYG | 1 | Mus musculus | D70 | PMAYMDASYFG | 1 | Rattus norvegicus | F227 | GGAVVFGGVDS | 1 | Homo sapiens | F227 | GGQIVFGGVDE | 1 | Mus musculus | F227 | GGQIVFGGVDK | 1 | Rattus norvegicus | F74 | MDAAYFGEISI | 1 | Homo sapiens | F74 | MDASYYGEISI | 1 | Mus musculus | F74 | MDASYFGEISI | 1 | Rattus norvegicus | F90 | NFLVLFDTGSS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G222 | QQGSNGGQIVF | 2 | Mus musculus, Rattus norvegicus | G222 | QQGSSGGAVVF | 1 | Homo sapiens | G223 | QGSNGGQIVFG | 2 | Mus musculus, Rattus norvegicus | G223 | QGSSGGAVVFG | 1 | Homo sapiens | G75 | DAAYFGEISIG | 1 | Homo sapiens | G75 | DASYYGEISIG | 1 | Mus musculus | G75 | DASYFGEISIG | 1 | Rattus norvegicus | I153 | LTVQSIQVPNQ | 2 | Homo sapiens, Rattus norvegicus | I153 | LRVQSIQVPNQ | 1 | Mus musculus | L205 | LGEGALSQPLF | 2 | Mus musculus, Rattus norvegicus | L205 | VQEGALTSPVF | 1 | Homo sapiens | L87 | PPQNFLVLFDT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M66 | VLYEPMAYMDA | 2 | Mus musculus, Rattus norvegicus | M66 | VTYEPMAYMDA | 1 | Homo sapiens | M69 | EPMAYMDAAYF | 1 | Homo sapiens | M69 | EPMAYMDASYY | 1 | Mus musculus | M69 | EPMAYMDASYF | 1 | Rattus norvegicus | N170 | NEPGTNFVYAQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Q151 | DTLTVQSIQVP | 2 | Homo sapiens, Rattus norvegicus | Q151 | DTLRVQSIQVP | 1 | Mus musculus | Q175 | NFVYAQFDGIM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T206 | GEGALSQPLFG | 2 | Mus musculus, Rattus norvegicus | T206 | QEGALTSPVFS | 1 | Homo sapiens | V150 | YDTLTVQSIQV | 2 | Homo sapiens, Rattus norvegicus | V150 | YDTLRVQSIQV | 1 | Mus musculus | V225 | SNGGQIVFGGV | 2 | Mus musculus, Rattus norvegicus | V225 | SSGGAVVFGGV | 1 | Homo sapiens | V226 | NGGQIVFGGVD | 2 | Mus musculus, Rattus norvegicus | V226 | SGGAVVFGGVD | 1 | Homo sapiens | Y173 | GTNFVYAQFDG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y73 | YMDAAYFGEIS | 1 | Homo sapiens | Y73 | YMDASYYGEIS | 1 | Mus musculus | Y73 | YMDASYFGEIS | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |